US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug

The U.S. government will pay as much as $2.6 billion for up to 1.25 million more doses of Regeneron’s COVID-19 antibody treatment, providing a boost to the Tarrytown, New York-based biotech after a slow initial uptake of the therapy.